INS and leukemia: This condition is induced by leukemia-driven production of insulin-like growth factor binding protein 1 (IGFBP1) from adipose tissue to mediate insulin sensitivity, and by loss of serotonin, microbiota-derived short-chain fatty acids and inactivation of incretin to suppress insulin secretion, resulting in an impairment of insulin/IGF1 function.